Share Twitter LinkedIn Facebook Email Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation. Advertisement
ASCO 2025: Lung Cancer Immunotherapy Breakthroughs from the Immuno-Oncology Symposium Lung Cancer Treatment 4 Mins Read